Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -44.23% is 19% below its 5-year average of -37.02%, near the high end of its 5-year range (-324.82%–-21.60%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.06% below its 12-month average of -42.50%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -44.23%.
RETURN ON EQUITY (ROE)
-44.23%
RETURN ON EQUITY (ROE) AVG TTM
-42.50%
RETURN ON EQUITY (ROE) AVG 3Y
-34.22%
RETURN ON EQUITY (ROE) AVG 5Y
-37.02%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.06%
CURRENT VS 3Y AVG
-29.26%
CURRENT VS 5Y AVG
-19.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.46%
median of 335 covered companies
CURRENT VS SECTOR MEDIAN
-55.42%
vs the sector median at left
Compass Therapeutics, Inc.
Market Cap
$172.99M
Return on Equity (ROE)
-44.23%
TTM Avg
-42.50%
3Y Avg
-34.22%
5Y Avg
-37.02%
Market Cap
$173.04M
Return on Equity (ROE)
-215.26%
TTM Avg
-150.35%
3Y Avg
8.65%
5Y Avg
-35.35%
Market Cap
$174.17M
Return on Equity (ROE)
-116.42%
TTM Avg
-18.43%
3Y Avg
-136.68%
5Y Avg
-137.61%
Market Cap
$176.96M
Return on Equity (ROE)
-7104.24%
TTM Avg
-166.54%
3Y Avg
-137.65%
5Y Avg
-112.46%
Market Cap
$179.70M
Return on Equity (ROE)
-21.57%
TTM Avg
-470.91%
3Y Avg
-299.18%
5Y Avg
-180.76%
Market Cap
$162.82M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
Market Cap
$184.12M
Return on Equity (ROE)
-19.01%
TTM Avg
-54.50%
3Y Avg
-75.60%
5Y Avg
-59.28%
Market Cap
$153.84M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$192.97M
Return on Equity (ROE)
-136.83%
TTM Avg
-43.45%
3Y Avg
-452.04%
5Y Avg
-306.86%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | $172.99M | -44.23% | -42.50% | -34.22% | -37.02% |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -215.26% | -150.35% | 8.65% | -35.35% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -116.42% | -18.43% | -136.68% | -137.61% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -7104.24% | -166.54% | -137.65% | -112.46% |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | -21.57% | -470.91% | -299.18% | -180.76% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -59.40% | -255.06% | -160.44% | -112.56% |
| Journey Medical Corporation (DERM)vs › | $184.12M | -19.01% | -54.50% | -75.60% | -59.28% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | -183.44% | -114.28% | -67.72% | -46.03% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -136.83% | -43.45% | -452.04% | -306.86% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -21.38% | -42.33% | -37.95% | -45.57% |
ROE
-44.2%
ROA
-38.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -44.23% |
| 2026-03-31 | -36.56% |
| 2025-12-31 | -33.79% |
| 2025-09-30 | -31.39% |
| 2025-06-30 | -66.55% |
| 2025-03-31 | -50.08% |
| 2024-12-31 | -39.43% |
| 2024-09-30 | -34.51% |
| 2024-06-30 | -32.33% |
| 2024-03-31 | -28.93% |
| 2023-12-31 | -28.61% |
| 2023-09-30 | -25.41% |
| 2023-06-30 | -25.36% |
| 2023-03-31 | -22.77% |
| 2022-12-31 | -21.60% |
| 2022-09-30 | -34.98% |
| 2022-06-30 | -27.27% |
| 2022-03-31 | -60.91% |
| 2021-12-31 | -58.67% |
| 2021-09-30 | -324.82% |
| 2021-06-30 | -279.71% |
| 2021-03-31 | -91.18% |
| 2020-12-31 | -73.85% |
| 2020-09-30 | -58.62% |
| 2020-06-30 | -50.94% |
| 2020-03-31 | -594.19% |
